Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 47, Issue -, Pages 244-250Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2017.04.004
Keywords
Ovarian cancer; Regulatory T cell; Surgery
Categories
Funding
- National Natural Science Foundation of China [81272324, 81371894, 81501817]
- Key Laboratory for Medicine of Jiangsu Province of China [XK201114]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Regulatory T cells (Treg) suppress immune responses in patients with cancer. Surgery is the most effective therapeutic strategy for ovarian cancer (OC). However, the interplay between the Treg population and surgical resection remains unclear. 61 patients with OC who received no prior treatment were enrolled in the study. Treg percentages were characterized from peripheral blood mononuclear cells. We investigated CD4(+) CD25(+), CD4(+) CD25(+) Foxp3(+), CD8(+) CD28(-), and CDS+ Foxp3(+) Tregs in OC patients and their postoperative changes using flow cytometry. Treg percentages were significantly higher in OC patients than those in benign ovarian tumors (BOT) and healthy controls. Higher percentages of Tregs were found in patients with stage III/IV than stage I/II OC. Treg percentages were significantly decreased postoperatively. The postoperative Treg percentages in patients with stage I/II OC were similar to those in BOT patients, while postoperative Treg percentages in patients with stage III/IV OC remained higher. Tregs were markedly lower on postoperative day (POD) 3 than preoperatively. They increased slightly after 7 days, but remained lower than preoperative levels. These data suggested that Tregs continued to decline from POD 7 to POD 30. Treg percentages are correlated with the tumor burden and could be a key factor in monitoring the immunological status of patients with OC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available